ClinicalTrials.gg
RecruitingNCT07688759Updated Jul 7, 2026

CMV-CMI in csCMVi After HSCT

An observational study in Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT) and Immune Reconstitution, sponsored by The First Affiliated Hospital of Soochow University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by The First Affiliated Hospital of Soochow University · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Cytomegalovirus Infections with a site in China — 8 open to participants now, 8 under way, none of them phase 3. Cytomegalovirus Infections · China.

Planned enrollment
11th of 12
40 · median 111
Started
2026
with 1 other
Observational
12 of 23
4 open now
Registered
23rd of 23
by date
Lead sponsor
5 of 23
The First Affiliated Hospital of Soochow University

Among the 23 studies in Cytomegalovirus Infections with a site in China, this one is the 11th largest by planned enrollment of the 12 observational ones that give a count, is one of 2 that started in 2026, is one of 12 observational ones, and was the 23rd registered.

Cytomegalovirus Infections

370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.

Browse Cytomegalovirus Infections studies →

Open to participants now

8 of the 23 studies in Cytomegalovirus Infections with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Cytomegalovirus Infections with a site in China, or all of them as a file.
02

Study summary

Cytomegalovirus (CMV) reactivation is a common and serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and the reconstitution of CMV-specific cell-mediated immunity (CMV-CMI) plays a key role in viral control.

This prospective, exploratory study will enroll 40 adult CMV-seropositive patients who experience their first CMV reactivation after allo-HSCT. CMV-specific T cell levels (IFN-γ-producing T cells stimulated by IE-1 and pp65 antigens) will be measured using ELISPOT at four time points: at diagnosis of CMV viremia, 3 weeks after initiating preemptive therapy, at anti-CMV drug withdrawal, and 4 weeks after treatment discontinuation. Patients will be followed for 12 weeks after stopping treatment.

The primary objective is to describe the changes in CMV-specific T cell levels over the therapy. Secondary objectives are to explore the relationship between these levels and the occurrence of refractory CMV infection, recurrent CMV infection, and CMV disease. Findings may help identify patients at high risk of progressing to severe or persistent CMV infection at an early stage of preemptive therapy, enabling personalized intervention strategies.

03

Conditions studied

  • Cytomegalovirus Infections
  • Hematopoietic Stem Cell Transplantation (HSCT)
  • Immune Reconstitution

Keywords

  • Cytomegalovirus
  • Hematopoietic Stem Cell Transplantation
  • Virus-specific T cells
  • cell-mediated immunity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of CMV-seropositive adults (≥18 years of age) who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT) and experience their first CMV reactivation after transplantation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years old and underwent hematopoietic stem cell transplantation (allo-HSCT);
  2. First CMV reactivation after transplantation;
  3. of ≥8 weeks;
  4. The participant (or legally acceptable representative, if applicable) has provided written for the trial.

Exclusion criteria

Exclusion Criteria:

  1. Recurrence of CMV infection;
  2. primary CMV infection in CMV-seronegative recipients (R-);
  3. Resistance to known anti-CMV drugs (ganciclovir, valganciclovir, foscarnet, maribavir, etc.);
  4. Currently receiving CMV-CTL treatment or lymphocyte infusion.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Target follow-up
12 Weeks
Patient registry
Yes

Groups and cohorts

  • CMV Reactivation Cohort

    Adult CMV-seropositive patients (≥18 years) who experience first CMV reactivation after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Therapy with anti-CMV drugs (mono- or combination therapy, at investigator's discretion) is initiated upon diagnosis of CMV viremia and continued until two consecutive negative CMV DNA tests separated by ≥5 days. CMV-specific T cell levels are measured by ELISPOT at four time points: at CMV viremia diagnosis, 3 weeks after starting preemptive therapy, at anti-CMV drug withdrawal, and 4 weeks after treatment discontinuation. Patients are followed for 12 weeks after treatment cessation.

    Drug: Anti-Cytomegalovirus Therapy

Interventions

  • DrugAnti-Cytomegalovirus Therapy

    The choice of agent (monotherapy or combination) is at the investigator's discretion and may include ganciclovir, valganciclovir, foscarnet, maribavir, or other approved anti-CMV medications.

06

What researchers measure

Primary outcomes

  1. CMV-specific T cells

    Number of IFN-γ-producing T cells per 250,000 PBMCs measured by ELISPOT

    Time frame: from baseline to 4 weeks after end of treatment, an average of 8 weeks

Secondary outcomes

  1. Cumulative incidence of refractory CMV infection

    Time frame: From Day 1 (first anti-CMV dose) through EOT (inclusive), an average of 4 weeks

  2. Cumulative incidence of CMV disease

    Time frame: From EOT+1 day through 12 weeks after EOT(end of follow-up)

  3. Cumulative incidence of recurrent CMV infection

    Time frame: From EOT+1 day through 12 weeks after EOT (end of follow-up)

  4. Cumulative incidence of acute graft-versus-host disease (aGVHD)

    Time frame: From Day 1 through 12 weeks after EOT (end of follow-up)

  5. Overall survival

    Time frame: From Day 1 through 12 weeks after EOT (end of follow-up).

Other outcomes

  1. Cumulative incidence of non-relapse mortality (NRM)

    Time frame: From Day 1 through 12 weeks after EOT (end of follow-up).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) for the primary and secondary outcome measures will be made available upon reasonable request to the principal investigator. Data will be shared after publication of the primary study results, for research purposes only, under a data transfer agreement that ensures compliance with ethical and confidentiality requirements. Supporting documents (study protocol, statistical analysis plan, and informed consent form) will be available as supplementary files.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2028, 23 months after the start.

Of 30 observational studies under Cytomegalovirus Infections, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 61. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2026
First posted
Jul 7, 2026
StartActual
Jun 1, 2026
Primary completionEst.
May 31, 2028
CompletionEst.
Aug 31, 2028
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07688759
Responsible party
Sponsor
First posted
Jul 7, 2026
Start date
Jun 1, 2026
Primary completion
May 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Jul 7, 2026

Study contacts

Feng Chen, MD
Contact
13584861215@163.com
+8613584861215

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion